By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) ...

A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...

Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...

The Vivani Medical Inc. combination appears to be over less than three years since its inception after the company reported ...

The company wants to create two focused companies dedicated to driving current and future value in their respective ...

Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while ...

Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...

Vivani Medical (VANI) announced that it intends to spin off Cortigent, a division that develops brain implant devices to help people recover ...

Vivani Medical, Inc. ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the successful administration of its ...

Vivani Medical (NASDAQ:VANI) said on Wednesday that it intends to divest its Cortigent unit, which builds neurostimulation ...

The decision is significant, as "it sets out principles whose scope exceeds the issue of the moratorium, affirming the unconstitutionality of regional regulations that conflict with the ...

Lucid Diagnostics Inc.  ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. , today announced that Highmark Blue Cross Blue ...